<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36951829</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6114</ISSN><JournalIssue CitedMedium="Internet"><Volume>183</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA internal medicine</Title><ISOAbbreviation>JAMA Intern Med</ISOAbbreviation></Journal><ArticleTitle>Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition.</ArticleTitle><Pagination><StartPage>554</StartPage><EndPage>564</EndPage><MedlinePgn>554-564</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamainternmed.2023.0743</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Post-COVID-19 condition (PCC), also known as long COVID, affects many individuals. Prevention of PCC is an urgent public health priority.</AbstractText><AbstractText Label="OBJECTIVE">To examine whether treatment with nirmatrelvir in the acute phase of COVID-19 is associated with reduced risk of PCC.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cohort study used the health care databases of the US Department of Veterans Affairs (VA) to identify patients who had a SARS-CoV-2 positive test result between January 3, 2022, and December 31, 2022, who were not hospitalized on the day of the positive test result, who had at least 1 risk factor for progression to severe COVID-19 illness, and who had survived the first 30 days after SARS-CoV-2 diagnosis. Those who were treated with oral nirmatrelvir within 5 days after the positive test (n&#x2009;=&#x2009;35&#x202f;717) and those who received no COVID-19 antiviral or antibody treatment during the acute phase of SARS-CoV-2 infection (control group, n&#x2009;=&#x2009;246&#x202f;076) were identified.</AbstractText><AbstractText Label="EXPOSURES">Treatment with nirmatrelvir or receipt of no COVID-19 antiviral or antibody treatment based on prescription records.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Inverse probability weighted survival models were used to estimate the association of nirmatrelvir (vs control) with post-acute death, post-acute hospitalization, and a prespecified panel of 13 post-acute COVID-19 sequelae (components of PCC) and reported in relative scale as relative risk (RR) or hazard ratio (HR) and in absolute scale as absolute risk reduction in percentage at 180 days (ARR).</AbstractText><AbstractText Label="RESULTS">A total of 281&#x202f;793 patients (mean [SD] age, 61.99 [14.96]; 242&#x202f;383 [86.01%] male) who had a positive SARS-CoV-2 test result and had at least 1 risk factor for progression to severe COVID-19 illness were studied. Among them, 246&#x202f;076 received no COVID-19 antiviral or antibody treatment during the acute phase of SARS-CoV-2 infection, and 35&#x202f;717 received oral nirmatrelvir within 5 days after the positive SARS-CoV-2 test result. Compared with the control group, nirmatrelvir was associated with reduced risk of PCC (RR, 0.74; 95% CI, 0.72-0.77; ARR, 4.51%; 95% CI, 4.01-4.99), including reduced risk of 10 of 13 post-acute sequelae (components of PCC) in the cardiovascular system (dysrhythmia and ischemic heart disease), coagulation and hematologic disorders (pulmonary embolism and deep vein thrombosis), fatigue and malaise, acute kidney disease, muscle pain, neurologic system (neurocognitive impairment and dysautonomia), and shortness of breath. Nirmatrelvir was also associated with reduced risk of post-acute death (HR, 0.53; 95% CI, 0.46-0.61); ARR, 0.65%; 95% CI, 0.54-0.77), and post-acute hospitalization (HR, 0.76; 95% CI, 0.73-0.80; ARR, 1.72%; 95% CI, 1.42-2.01). Nirmatrelvir was associated with reduced risk of PCC in people who were unvaccinated, vaccinated, and boosted, and in people with primary SARS-CoV-2 infection and reinfection.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This cohort study found that in people with SARS-CoV-2 infection who had at least 1 risk factor for progression to severe disease, treatment with nirmatrelvir within 5 days of a positive SARS-CoV-2 test result was associated with reduced risk of PCC across the risk spectrum in this cohort and regardless of vaccination status and history of prior infection; the totality of findings suggests that treatment with nirmatrelvir during the acute phase of COVID-19 may reduce the risk of post-acute adverse health outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Center, Research and Development Service, VA St Louis Health Care System, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Research and Education Foundation of St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Taeyoung</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Center, Research and Development Service, VA St Louis Health Care System, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Research and Education Foundation of St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Aly</LastName><ForeName>Ziyad</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Center, Research and Development Service, VA St Louis Health Care System, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Research and Education Foundation of St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nephrology Section, Medicine Service, VA St Louis Health Care System, St Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Public Health, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Intern Med</MedlineTA><NlmUniqueID>101589534</NlmUniqueID><ISSNLinking>2168-6106</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Intern Med. 2023 Jun 1;183(6):565. doi: 10.1001/jamainternmed.2023.0760</RefSource><PMID Version="1">36951848</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Al-Aly reported receiving consultation fees from Gilead Sciences and Tonix Pharmaceuticals and consulting (uncompensated) for Pfizer.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>23</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36951829</ArticleId><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="doi">10.1001/jamainternmed.2023.0743</ArticleId><ArticleId IdType="pii">2802878</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259-264. doi:10.1038/s41586-021-03553-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28(7):1461-1467. doi:10.1038/s41591-022-01840-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375(6585):1122-1127. doi:10.1126/science.abm8108</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. Long-COVID treatments: why the world is still waiting. Nature. 2022;608(7922):258-260. doi:10.1038/d41586-022-02140-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-02140-w</ArticleId><ArticleId IdType="pubmed">35945375</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, et al. ; EPIC-HR Investigators . Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397-1408. doi:10.1056/NEJMoa2118542</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kind AJH, Buckingham WR. Making neighborhood-disadvantage metrics accessible&#x2014;the neighborhood atlas. N Engl J Med. 2018;378(26):2456-2458. doi:10.1056/NEJMp1802313</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1802313</ArticleId><ArticleId IdType="pmc">PMC6051533</ArticleId><ArticleId IdType="pubmed">29949490</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen K, Ren S, Heath K, et al. . Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2022;376:e068414. doi:10.1136/bmj-2021-068414</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068414</ArticleId><ArticleId IdType="pmc">PMC8828141</ArticleId><ArticleId IdType="pubmed">35140117</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L, Baca S, Saydah S, et al. . Post&#x2013;COVID conditions among adult COVID-19 survivors aged 18-64 and &#x2265;65 years&#x2014;United States, March 2020-November 2021. MMWR Morb Mortal Wkly Rep. 2022;71(21):713-717. doi:10.15585/mmwr.mm7121e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7121e1</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty SE, Guo Y, Heath K, et al. . Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021;373(1098):n1098. doi:10.1136/bmj.n1098</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1098</ArticleId><ArticleId IdType="pmc">PMC8132065</ArticleId><ArticleId IdType="pubmed">34011492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Khunti K, Nafilyan V, et al. . Post-COVID syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study. BMJ. 2021;372(693):n693. doi:10.1136/bmj.n693</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n693</ArticleId><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, Gemelli Against C-P-ACSG; Gemelli Against COVID-19 Post-Acute Care Study Group . Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603-605. doi:10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Bowe B, Al-Aly Z. Burdens of post&#x2013;acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat Commun. 2021;12(1):6571. doi:10.1038/s41467-021-26513-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26513-3</ArticleId><ArticleId IdType="pmc">PMC8589966</ArticleId><ArticleId IdType="pubmed">34772922</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):e1003773. doi:10.1371/journal.pmed.1003773</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Xu E, Al-Aly Z.. Kidney outcomes in long COVID. J Am Soc Nephrol. 2021;32(11):2851-2862. doi:10.1681/ASN.2021060734</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2021060734</ArticleId><ArticleId IdType="pmc">PMC8806085</ArticleId><ArticleId IdType="pubmed">34470828</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with COVID-19: cohort study. BMJ. 2022;376:e068993. doi:10.1136/bmj-2021-068993</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068993</ArticleId><ArticleId IdType="pmc">PMC8847881</ArticleId><ArticleId IdType="pubmed">35172971</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi:10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236&#x2009;379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416-427. doi:10.1016/S2215-0366(21)00084-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022;10(5):311-321. doi:10.1016/S2213-8587(22)00044-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(22)00044-4</ArticleId><ArticleId IdType="pmc">PMC8937253</ArticleId><ArticleId IdType="pubmed">35325624</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu E, Xie Y, Al-Aly Z. Long-term neurologic outcomes of COVID-19. Nat Med. 2022;28(11):2406-2415. doi:10.1038/s41591-022-02001-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02001-z</ArticleId><ArticleId IdType="pmc">PMC9671811</ArticleId><ArticleId IdType="pubmed">36138154</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu E, Xie Y, Al-Aly Z. Risks and burdens of incident dyslipidaemia in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2023;11(2):120-128. doi:10.1016/S2213-8587(22)00355-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(22)00355-2</ArticleId><ArticleId IdType="pmc">PMC9873268</ArticleId><ArticleId IdType="pubmed">36623520</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu E, Xie Y, Al-Aly Z. Long-term gastrointestinal outcomes of COVID-19. Nat Commun. 2023;14(983). doi:10.1038/s41467-023-36223-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-36223-7</ArticleId><ArticleId IdType="pmc">PMC9992516</ArticleId><ArticleId IdType="pubmed">36882400</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med. 2022;28(11):2398-2405. doi:10.1038/s41591-022-02051-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02051-3</ArticleId><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulf Hanson S, Abbafati C, Aerts JG, et al. ; Global Burden of Disease Long COVID Collaborators . Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604-1615. doi:10.1001/jama.2022.18931</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Bowe B, Maddukuri G, Al-Aly Z. Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with COVID-19 and seasonal influenza: cohort study. BMJ. 2020;371:m4677. doi:10.1136/bmj.m4677</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4677</ArticleId><ArticleId IdType="pmc">PMC7735416</ArticleId><ArticleId IdType="pubmed">33323357</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Cai M, Xie Y, Gibson AK, Maddukuri G, Al-Aly Z. Acute kidney injury in a national cohort of hospitalized US veterans with COVID-19. Clin J Am Soc Nephrol. 2020;16(1):14-25. doi:10.2215/CJN.09610620</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.09610620</ArticleId><ArticleId IdType="pmc">PMC7792643</ArticleId><ArticleId IdType="pubmed">33199414</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Bowe B, Al-Aly Z. Molnupiravir and risk of hospitalization or death: a target trial emulation using the US Veterans Affairs healthcare databases. BMJ. 2023;380:e072705. doi:10.13039/100000738</Citation><ArticleIdList><ArticleId IdType="doi">10.13039/100000738</ArticleId><ArticleId IdType="pmc">PMC9989554</ArticleId><ArticleId IdType="pubmed">36882199</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Agarwal A, Alwan N, Luyckx VA. Long COVID: long-term health outcomes and implications for policy and research. Nat Rev Nephrol. 2022;19(1):1-2. doi:10.1038/s41581-022-00652-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-022-00652-2</ArticleId><ArticleId IdType="pmc">PMC9628426</ArticleId><ArticleId IdType="pubmed">36319780</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z. Diabetes after SARS-CoV-2 infection. Lancet Diabetes Endocrinol. 2023;11(1):11-13. doi:10.1016/S2213-8587(22)00324-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(22)00324-2</ArticleId><ArticleId IdType="pmc">PMC9714974</ArticleId><ArticleId IdType="pubmed">36463908</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani S, Mohri H, Culbertson B, et al. . Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature. 2023;613(7944):558-564. doi:10.1038/s41586-022-05514-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05514-2</ArticleId><ArticleId IdType="pmc">PMC9849135</ArticleId><ArticleId IdType="pubmed">36351451</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>